Fig. 4

Transgenic T cell therapy extends survival in mice bearing syngeneic brainstem tumors. (a) Kaplan-Meier survival curve for B16-ova tumors were treated with PBS or pmel T cells, followed 4–6 h later by PBS or VSV-hgp100 and two follow-up doses of VSV-hgp100 or PBS. (n = 9 mice/group) Figure is representative of three independent experiments. (b) Kaplan-Meier survival curve for mice bearing GL261-QUAD tumors treated with PBS or OT-I T cells, followed 4–6 h later by PBS or VSV-ova and two follow-up doses of VSV-ova or PBS. (n = 18 mice/group) Figure is representative of one experiment